Medication info
Sitagliptin and Metformin Extended Release Tablets 50/1000 mg

Sitagliptin and Metformin Extended Release Tablets 50/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Allegro Pharmaceuticals Co., Ltd.
Appearance
Bright green, oval-shaped, biconvex extended-release film-coated tablet
Packaging
Bottle packaging - 28 tablets/bottle, Bottle packaging - 56 tablets/bottle, Bottle packaging - 200 tablets/bottle
Approval status
Active

MFDS item code 202202015 · Approved 2022.05.13 · Insurance code 656005370

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with a meal, preferably in the evening, and increase the dose gradually. To preserve the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take one 100/1000 mg extended-release tablet once daily. Patients taking the 50/500 mg or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose cannot be adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control is not achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine. 2. Patients receiving metformin: For patients whose blood glucose cannot be adequately controlled with metformin monotherapy, the recommended initial total daily dose of this medicine is sitagliptin 100 mg and the current metformin dose. Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. Patients previously taking immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start this medicine at 2 tablets of 50/1000 mg extended-release tablets once daily. 3. Patients whose blood glucose cannot be adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg. The initial dose of metformin should be determined taking the patient's blood glucose level and current dose into consideration. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because of its metformin component.

Ingredients

Manufacturer
Allegro Pharmaceuticals Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to help patients with type 2 diabetes manage their blood glucose levels. When taken together with dietary and exercise therapy, it can effectively control blood sugar levels. Since sitagliptin and metformin work together to help lower blood sugar, it is suitable for patients who have difficulty managing their blood glucose levels. Regular use of this medication can be expected to have a positive effect on diabetes management.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine once daily with a meal, preferably in the evening, and increase the dose gradually. To preserve the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take one 100/1000 mg extended-release tablet once daily. Patients taking the 50/500 mg or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose cannot be adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control is not achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine. 2. Patients receiving metformin: For patients whose blood glucose cannot be adequately controlled with metformin monotherapy, the recommended initial total daily dose of this medicine is sitagliptin 100 mg and the current metformin dose. Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. Patients previously taking immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start this medicine at 2 tablets of 50/1000 mg extended-release tablets once daily. 3. Patients whose blood glucose cannot be adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg. The initial dose of metformin should be determined taking the patient's blood glucose level and current dose into consideration. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because of its metformin component.

Precautions

This medication contains sitagliptin and metformin, which are used for diabetes treatment. Serious allergic reactions may occur while taking this medication, so if you experience symptoms such as rash, hives, difficulty breathing, or swelling of the face or neck, you should stop taking the medication immediately and seek medical attention. Additionally, there is a risk of pancreatitis; therefore, if you experience sudden abdominal pain, nausea, vomiting, or fever, you should consult a physician immediately. Rarely, life-threatening lactic acidosis may occur due to the metformin component; if you experience sudden fatigue, muscle pain, difficulty breathing, abdominal pain, or decreased consciousness, you must seek immediate medical treatment. This medication should not be taken by individuals with severely impaired kidney function or certain serious conditions such as severe infections, dehydration, acute myocardial infarction, or heart failure. You must stop taking this medication before and after undergoing procedures that use iodinated contrast agents and re-administer it only after confirming kidney function. It is safest not to use this medication during pregnancy or while breastfeeding, nor in children under 18 years of age. While taking this medication, you should be cautious of symptoms of hypoglycemia, especially when taking it in combination with insulin or sulfonylureas, as the risk of hypoglycemia is increased, so it is important to monitor symptoms carefully. Alcohol consumption may increase the risk of lactic acidosis; therefore, it is advisable to avoid alcohol while taking this medication. Also, if you are facing surgery or experiencing severe infections, dehydration, or severe trauma, you should temporarily discontinue this medication and resume it only after normal recovery of oral intake and confirmation of normal kidney function. Regular blood tests and kidney function assessments are important to detect any abnormalities. While taking this medication, continue to maintain a consistent diet and exercise regimen, and if you experience any related symptoms or adverse reactions, consult your healthcare provider immediately.

Side effects

Severe hypersensitivity reactions, anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory infections, headache, nausea, vomiting, abdominal pain, nasopharyngitis, constipation, arthralgia with severe and disabling symptoms, blistering dermatitis herpetiformis, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, elevated liver enzymes, acute renal failure, hypoglycemic episodes, rash, urticaria, cutaneous vasculitis

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to protect it from air and moisture, and keep it at room temperature between 1 and 30 degrees Celsius. This will help maintain the medication's effectiveness for a longer period.

Appearance and packaging

Appearance

Bright green, oval-shaped, biconvex extended-release film-coated tablet

Package unit

Bottle packaging - 28 tablets/bottle, Bottle packaging - 56 tablets/bottle, Bottle packaging - 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.